Physician profile
Kathrin Lafaver
NPI 1528188836
$14,832.19
in general payments reported to CMS, 2019-2025
16 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2020: $8,905 · 2021: $3,175 · 2022: $186 · 2023: $63.92 · 2024: $329 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $8,905.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $3,075.00 | 2021 | |
| Biogen, INC. | $1,122.60 | 2019 | |
| Boston Scientific Corporation | $395.30 | 2019 | |
| Argenx US, INC. | $354.17 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $194.70 | 2019 | |
| Sk Life Science, INC. | $174.62 | 2021-2022 | |
| Neurelis, INC. | $120.54 | 2024 | Valtoco |
| Ucb, INC. | $99.36 | 2025 | Rystiggo |
| Mdd US Operations, LLC | $81.30 | 2019 | |
| Amneal Pharmaceuticals LLC | $78.77 | 2024 | Crexont |
| Abbvie INC. | $73.33 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $72.06 | 2021-2022 | |
| Ge Healthcare | $49.46 | 2023 | |
| Livanova USA, INC. | $35.98 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathrin Lafaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.